Targeting cancer-initiating cell drug-resistance: A Sroadmap to a new-generation of cancer therapies?

Research output: Contribution to journalArticle

Abstract

The occurrence of drug resistance in oncology accounts for treatment failure and relapse of diverse tumor types. Cancers contain cells at various stages of differentiation together with a limited number of 'cancer-initiating cells' able to self-renew and divide asymmetrically, driving tumorigenesis. Cancer-initiating cells display a range of self-defense systems that include almost all mechanisms of drug-resistance. Different molecular pathways and markers, identified in this malignant sub-population, are becoming targets for novel compounds and for monoclonal antibodies, which may be combined with conventional drugs. These interventions might eliminate drug-resistant cancer-initiating cells and lead to remission or cure of cancer patients.

Original languageEnglish
Pages (from-to)435-442
Number of pages8
JournalDrug Discovery Today
Volume17
Issue number9-10
DOIs
Publication statusPublished - May 2012

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Targeting cancer-initiating cell drug-resistance: A Sroadmap to a new-generation of cancer therapies?'. Together they form a unique fingerprint.

Cite this